Great review on therapies upon failure of HMA+Ven for patients with AML in the #ASH23 educational book by Dr Alison Walker and Dr Onyee Chan ASH Moffitt Cancer Center ashpublications.org/hematology/art…

Interesting real world data presented by Talha Badar in pts w ND TP53 mutant AML with HMA+Ven vs HMA alone. CRc rates, DOR and AlloSCT rates improved with HMA/Ven, but no OS (9 vs 7 mo) or EFS difference #ASH23 #leusm Mayo Clinic ASH

Getting ready for the last day of #ASH23, can’t wait for the late breaking abstract session! ASH

Apart from the great science and seeing friends, what I’ll miss the most about #ASH23 is the amazing authentic Mexican food in San Diego! Tacos, chilaquiles, amazing!! Can’t wait for #ASH24 ASH

One of the busiest places at #ASH23, the Starbucks line, have to get coffee before the sessions!!

Starting strong the late breaking abstract session, Pieter Sonnenveld presenting the PERSEUS trial in NDMM for pts eligible for ASCT, stating that Dara-VRd is the new standard of care #ASH23 curious to know what my myeloma friends think Al-Ola A Abdallah MD (USMIRC) Nausheen Ahmed MD Mateo Mejia

LBA-2 Michael Wang presented results of the SYMPATICO Ph3 trial in R/R Mantle Cell Lymphoma with Ibrutinib/Ven vs Ibrutinib showing better response and PFS, OS numerically better, also stated new standard of care, curious to her from my lymphoma friends #ASH23 ASH

Revumenib in R/R KMT2Ar Acute Leukemia presented by Dr Ibrahim Aldoss City of Hope at the #latebreaking abstract session, 57 pts 83% w AML, 50% prior SCT, ORR of 63% and CRc of 44% and MRD negative in 68% of these, in a heavily pretreated population. #ASH23 ASH

Couldn’t agree more 🌮 🌮 🌮 🌮 🌮 #ASH23

Cannot leave #ASH23 without going again to Tacos El Gordo 🌮 🌮 🌮 🇲🇽 🇲🇽 🇲🇽 Ioannis Mantzaris

Now at The Best of #ASH23 Jad Othman The Benefit of AlloSCT in 1st CR in NPM1 Mutated AML with or w/o FLT3 ITD Is Restricted to Those Testing MRD+ after Induction, those MRD negative in blood after 2 inductions show no survival benefit from Allo even in FLT3-ITD comutation

Really liked the social media hub #ASH23

Not bad for a slow last day at #ASH23, it’s only 2 pm!

Interesting data from Junya Sango highlighted on the best of #ASH23 N/KRAS mutant AML LSCs from myelomonocytic progenitors drive resistance to VEN Marina Konopleva Eirini Papapetrou, MD, PhD ASH

Can’t believe #ASH23 is over it was great science, tacos 🌮, city (San Diego!), and always go back home recharged with ideas and passion to continue helping my patients great seeing my mentors and friends Amit Verma Aditi Shastri, MD Ioannis Mantzaris Heather J. Male, MD, MBA Tara Lin and many more

#ASH23 a point I had totally missed - thanks Mateo Mejia! For those implementing GRIFFIN or PERSEUS for #MMsm, we suggest GRIFFINDOR (named by Gurbakhash Kaur): 👉🏼 Dara per label 👉🏼 V D1,8,15 (I sometimes drop D8 dose once in VGPR) 👉🏼 R 21/28 days 👉🏼 dex 20mg once-weekly to off

Me during a conference: "I am so motivated, I will work on the plane back home and respond to all emails" Me on the plane:

#ASH23 in a nutshell🤣

NEW: a cohort study on CCUS suggests high-risk mutations and their number are predictive of survival warranting clinical surveillance & advises mutation analysis in patients with available bone marrow samples #cytopenias thelancet.com/journals/lanha…

Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-mutated MDS sciencedirect.com/science/articl…